Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Arvinas Holding Company ( (ARVN) ) just unveiled an announcement.
On June 4, 2025, Ian Taylor, Ph.D., President of Research and Development at Arvinas, Inc., announced his resignation effective June 6, 2025, to retire. Despite stepping down, Dr. Taylor will continue to contribute to the company by entering a Consulting Agreement to provide advisory services for one year and will remain as chair of the Scientific Advisory Board.
The most recent analyst rating on (ARVN) stock is a Buy with a $87.00 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.
Spark’s Take on ARVN Stock
According to Spark, TipRanks’ AI Analyst, ARVN is a Neutral.
The overall score reflects strong strategic developments in clinical trials and cost-saving initiatives, but is tempered by ongoing profitability challenges and negative cash flows. Technical indicators and valuation also suggest risks.
To see Spark’s full report on ARVN stock, click here.
More about Arvinas Holding Company
Average Trading Volume: 3,089,836
Technical Sentiment Signal: Sell
Current Market Cap: $507.3M
For a thorough assessment of ARVN stock, go to TipRanks’ Stock Analysis page.